With PI3Kδ being the most likely isoform of PI3K to target in acute leukemia, myelosuppression at efficacious doses was manageable demonstrating that a therapeutic window for PI3Kδ isotype specific inhibition may exist. This evidence concerns the gene PIK3CA and acute leukemia.